127 related articles for article (PubMed ID: 38563084)
1. DLC1 promotes mechanotransductive feedback for YAP via RhoGAP-mediated focal adhesion turnover.
Hooglugt A; van der Stoel MM; Shapeti A; Neep BF; de Haan A; van Oosterwyck H; Boon RA; Huveneers S
J Cell Sci; 2024 Apr; 137(8):. PubMed ID: 38563084
[TBL] [Abstract][Full Text] [Related]
2. DLC1 is a direct target of activated YAP/TAZ that drives collective migration and sprouting angiogenesis.
van der Stoel M; Schimmel L; Nawaz K; van Stalborch AM; de Haan A; Klaus-Bergmann A; Valent ET; Koenis DS; van Nieuw Amerongen GP; de Vries CJ; de Waard V; Gloerich M; van Buul JD; Huveneers S
J Cell Sci; 2020 Feb; 133(3):. PubMed ID: 31964713
[TBL] [Abstract][Full Text] [Related]
3. YAP and TAZ limit cytoskeletal and focal adhesion maturation to enable persistent cell motility.
Mason DE; Collins JM; Dawahare JH; Nguyen TD; Lin Y; Voytik-Harbin SL; Zorlutuna P; Yoder MC; Boerckel JD
J Cell Biol; 2019 Apr; 218(4):1369-1389. PubMed ID: 30737263
[TBL] [Abstract][Full Text] [Related]
4. DLC1 deficiency and YAP signaling drive endothelial cell contact inhibition of growth and tumorigenesis.
Ritchey L; Ha T; Otsuka A; Kabashima K; Wang D; Wang Y; Lowy DR; Tosato G
Oncogene; 2019 Nov; 38(45):7046-7059. PubMed ID: 31409902
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of DLC1 in endothelial cells compromises the angiogenesis process.
Shih YP; Yuan SY; Lo SH
Cancer Lett; 2017 Jul; 398():46-51. PubMed ID: 28408355
[TBL] [Abstract][Full Text] [Related]
6. CCM3 is a gatekeeper in focal adhesions regulating mechanotransduction and YAP/TAZ signalling.
Wang S; Englund E; Kjellman P; Li Z; Ahnlide JK; Rodriguez-Cupello C; Saggioro M; Kanzaki R; Pietras K; Lindgren D; Axelson H; Prinz CN; Swaminathan V; Madsen CD
Nat Cell Biol; 2021 Jul; 23(7):758-770. PubMed ID: 34226698
[TBL] [Abstract][Full Text] [Related]
7. Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1.
Tripathi BK; Grant T; Qian X; Zhou M; Mertins P; Wang D; Papageorge AG; Tarasov SG; Hunter KW; Carr SA; Lowy DR
J Cell Biol; 2017 Dec; 216(12):4255-4270. PubMed ID: 29114068
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor activates the Rho GTPase-activating protein (GAP) Deleted in Liver Cancer 1 via focal adhesion kinase and protein phosphatase 2A.
Ravi A; Kaushik S; Ravichandran A; Pan CQ; Low BC
J Biol Chem; 2015 Feb; 290(7):4149-62. PubMed ID: 25525271
[TBL] [Abstract][Full Text] [Related]
9. YAP/TAZ-CDC42 signaling regulates vascular tip cell migration.
Sakabe M; Fan J; Odaka Y; Liu N; Hassan A; Duan X; Stump P; Byerly L; Donaldson M; Hao J; Fruttiger M; Lu QR; Zheng Y; Lang RA; Xin M
Proc Natl Acad Sci U S A; 2017 Oct; 114(41):10918-10923. PubMed ID: 28973878
[TBL] [Abstract][Full Text] [Related]
10. Tensin1 positively regulates RhoA activity through its interaction with DLC1.
Shih YP; Sun P; Wang A; Lo SH
Biochim Biophys Acta; 2015 Dec; 1853(12):3258-65. PubMed ID: 26427649
[TBL] [Abstract][Full Text] [Related]
11. FAK, vinculin, and talin control mechanosensitive YAP nuclear localization.
Holland EN; Fernández-Yagüe MA; Zhou DW; O'Neill EB; Woodfolk AU; Mora-Boza A; Fu J; Schlaepfer DD; García AJ
Biomaterials; 2024 Jul; 308():122542. PubMed ID: 38547833
[TBL] [Abstract][Full Text] [Related]
12. Lysophosphatidic acid-induced YAP/TAZ activation promotes developmental angiogenesis by repressing Notch ligand Dll4.
Yasuda D; Kobayashi D; Akahoshi N; Ohto-Nakanishi T; Yoshioka K; Takuwa Y; Mizuno S; Takahashi S; Ishii S
J Clin Invest; 2019 Jul; 129(10):4332-4349. PubMed ID: 31335323
[TBL] [Abstract][Full Text] [Related]
13. Nuclear-targeted deleted in liver cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo.
Chan LK; Ko FC; Sze KM; Ng IO; Yam JW
PLoS One; 2011; 6(9):e25547. PubMed ID: 21966542
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of CCM3 promotes angiogenesis through activation and nuclear translocation of YAP/TAZ.
Tang L; Zhou M; Xu Y; Peng B; Gao Y; Mo Y
Biochem Biophys Res Commun; 2024 Mar; 701():149525. PubMed ID: 38320423
[TBL] [Abstract][Full Text] [Related]
15. A YAP/TAZ-ARHGAP29-RhoA Signaling Axis Regulates Podocyte Protrusions and Integrin Adhesions.
Rogg M; Maier JI; Helmstädter M; Sammarco A; Kliewe F; Kretz O; Weißer L; Van Wymersch C; Findeisen K; Koessinger AL; Tsoy O; Baumbach J; Grabbert M; Werner M; Huber TB; Endlich N; Schilling O; Schell C
Cells; 2023 Jul; 12(13):. PubMed ID: 37443829
[TBL] [Abstract][Full Text] [Related]
16. Regulation of deleted in liver cancer 1 tumor suppressor by protein-protein interactions and phosphorylation.
Ko FC; Ping Yam JW
Int J Cancer; 2014 Jul; 135(2):264-9. PubMed ID: 24114040
[TBL] [Abstract][Full Text] [Related]
17. Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).
Li G; Du X; Vass WC; Papageorge AG; Lowy DR; Qian X
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17129-34. PubMed ID: 21969587
[TBL] [Abstract][Full Text] [Related]
18. TNF-α-Induced YAP/TAZ Activity Mediates Leukocyte-Endothelial Adhesion by Regulating VCAM1 Expression in Endothelial Cells.
Choi HJ; Kim NE; Kim BM; Seo M; Heo JH
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30388809
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of YAP/TAZ in vascular mechanotransduction and disease.
Ritsvall O; Albinsson S
Microcirculation; 2024 May; 31(4):e12838. PubMed ID: 38011540
[TBL] [Abstract][Full Text] [Related]
20. Deleted in liver cancer 1 (DLC1) utilizes a novel binding site for Tensin2 PTB domain interaction and is required for tumor-suppressive function.
Chan LK; Ko FC; Ng IO; Yam JW
PLoS One; 2009; 4(5):e5572. PubMed ID: 19440389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
